← Halozyme Therapeutics, Inc. (HALO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Halozyme Therapeutics, Inc. (HALO)
Biological Products, (No Diagnostic Substances) · market cap $12.9B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
9
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Halozyme Therapeutics (HALO) is a San Diego-based biotech best known for its ENHANZE drug-delivery technology platform, which enables subcutaneous administration of biologics via its recombinant human hyaluronidase (rHuPH20). With $1.4B in 2025 revenue and a $9.3B market cap, the company operates primarily as a technology licensor to large pharma partners rather than a pure-play drug developer, though it retains its own pipeline including Hylenex in Phase 3 for Pain. The balance sheet carries $1.83B in net debt against $310M cash, a meaningful leverage overhang on an otherwise profitable business.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Humulin-R | Phase 2 | Diabetes Mellitus, Type 2 |
| Insulin aspart | Phase 2 | Diabetes Mellitus, Type II |
| Mitomycin C | Phase 2 | Bladder Cancer |
| Humalog | Phase 2 | Type 1 Diabetes Mellitus |
| PEGPH20 | Phase 2 | Metastatic Pancreatic Cancer |
| rHuPH20 | Phase 2 | Dermatitis, Allergic Contact |
| regular human insulin | Phase 2 | Diabetes Mellitus, Type 1 |
| Hylenex | Phase 3 | Pain |
| Insulin lispro | Phase 2 | Diabetes Mellitus, Type 1 |
Price & technical context
3-month
+43.4%
6-month
+70.8%
12-month
+50.6%
52-wk range
$61.63–$115.22
vs 50-day MA
+8.5%
vs 200-day MA
+41.8%
Realized vol
36.3%
Max drawdown
-32.3%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for HALO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.